KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
128 hedge funds and large institutions have $557M invested in KalVista Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 11 closing their positions.
318% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 11
38% more funds holding
Funds holding: 93 → 128 (+35)
22% more capital invested
Capital invested by funds: $459M → $557M (+$98.6M)
3.05% more ownership
Funds ownership: 108.32% → 111.37% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 35
86% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $7.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$28.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$24.9M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$20.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$19.5M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$29.8M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$13.9M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.29M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.49M |
KALV Hedge Fund Activity: Q1 2024 in Review
128 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2024, worth a combined $557M — up 22% from $459M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new KALV positions and 11 closed out — a net gain of 35 holders — while 33 added to existing stakes and 35 trimmed.
The largest buyer was VR Adviser, adding an estimated $28.8M. The largest seller was TCG Crossover Management, cutting an estimated $29.8M.
- 128 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2024, up from 93 in Q4 2023.
- Funds reported $557M of KalVista Pharmaceuticals stock for Q1 2024, up 22% quarter-over-quarter.
- 46 funds opened new KalVista Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +35 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2024 was VR Adviser, an estimated $28.8M added.
- The largest KalVista Pharmaceuticals seller in Q1 2024 was TCG Crossover Management, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2024.